Masimo Corporation was incorporated in California in May 1989 and re-incorporated in Delaware in May 1996. The Company is a global medical technology company that develops, manufactures and markets non-invasive patient monitoring products. The company's mission is to improve patient outcomes and reduce care costs by bringing non-invasive monitoring to new sites and applications. The company invented the Masimo signal extraction technology, Masimo SET, which provides the ability to measure movement and low perfusion pulse oximeters to address the main limitations of traditional pulse oximeters. Pulse oximeters are non-invasive measures of arterial oxygen saturation levels, or the blood that delivers oxygen to human tissue, as well as pulse rate. Pulse oximeters are one of the most common measurements taken in and out of hospitals around the world. Validated in more than 100 independent clinical studies, Masimo SET is the only pulse oximeter technology known to the company that has been shown to help clinicians detect critical congenital heart disease in newborns, reduce retinopathy in preterm newborns, and reduce intensive care unit metastases and rapid response activation on general floors. The company's products include a monitor or circuit board for its proprietary single-patient use and reusable sensors and cables. The Company sells its products to end users through its direct sales force and certain distributors, and sells some of the Company's products to its original equipment manufacturers or OEM partners for inclusion in products.
